Atypical Teratoid Rhabdoid Tumor | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

29,883 results for “Atypical Teratoid Rhabdoid Tumor”

Trials

View all 22120 →

Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor

416 participants · First posted Jun 11, 2004

Study of Novel Therapies for Young People With Recurrent/Progressive Atypical Teratoid Rhabdoid Tumor (ATRT)

29 participants · First posted Mar 3, 2026

Active, not recruiting

Feasibility of Using Bortezomib with or Without Chemotherapy in Patients with Atypical Teratoid/rhabdoid Tumors

6 participants · First posted Feb 28, 2025

Drugs

View all 590 →

atypical antipsychotics (Lilly)

DBI-500

SEP-226929

Organizations

View all 63 →

Stiftung Swiss Tumor Institute

Switzerland

National Center for Tumor Diseases

Germany

The Fourth Hospital of Hebei Medical University (Hebei Tumor Hospital)

China

News

View all 7110 →

Aminex Therapeutics Initiates Phase 1b/2 Trial of Novel Polyamine-Targeting Cancer Therapy AMXT 1501 Plus DFMO

Lantern Pharma Receives FDA Guidance for Pediatric CNS Cancer Trial Targeting ATRT

Kazia Therapeutics Doses First Patient in PNOC035 Phase 2 Trial of Paxalisib Plus Gemcitabine for Recurrent Pediatric AT/RT

Page 1 of 2989